In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC), announces the following meeting of the aforementioned committee:
Time and Date: 9 a.m.-5 p.m., Eastern Standard Time, December 1, 2015
Place: Jacob J. Javits Federal Building, 26 Federal Plaza, New York, New York 10278. This meeting is also available by teleconference. The USA toll-free, dial-in number is 1-888-455-9749, and when prompted enter passcode—6542002. To view the web conference, enter the following web address in your web browser: https://odniosh.adobeconnect.com/wtchpstac/.
Public Comment Time and Date: 11:20 a.m.-12 p.m., Eastern Standard Time, December 1, 2015
Please note that the public comment period ends at the time indicated above or following the last call for comments, whichever is earlier. Members of the public who want to comment must sign up by providing their name by mail, email, or telephone, at the addresses provided below by November 27, 2015. Each commenter will be provided up to five minutes for comment. A limited number of time slots are available and will be assigned on a first come-first served basis. Written comments will also be accepted from those unable to attend the public session.
Status: Open to the public, limited only by the number of telephone lines. The conference line will accommodate up to 50 callers; therefore it is suggested that those interested in calling in to listen to the committee meeting share a line when possible.
Background: The Advisory Committee was established by Public Law 111-347 (The James Zadroga 9/11 Health and Compensation Act of 2010, Title XXXIII of the Public Health Service Act), enacted on January 2, 2011 and codified at 42 U.S.C. 300mm-300mm-61.
Purpose: The purpose of the Advisory Committee is to review scientific and medical evidence and to make recommendations to the Administrator of the World Trade Center (WTC) Health Program regarding additional WTC Health Program eligibility criteria and potential additions to the list of covered WTC-related health conditions, as well as providing consultation on research to the Administrator of the World Trade Center Health Program. Title XXXIII of the Public Health Service Act established within the Department of Health and Human Services (HHS), the World Trade Center (WTC) Health Program, to be administered by the Administrator of the World Trade Center Health Program. The WTC Health Program provides: (1) Medical monitoring and treatment benefits to eligible emergency responders and recovery and cleanup workers (including those who are Federal employees) who responded to the September 11, 2001, terrorist attacks, and (2) initial health evaluation, monitoring, and treatment benefits to residents and other building occupants and area workers in New York City, who were directly impacted and adversely affected by such attacks (“survivors”). Certain specific activities of the Administrator of the World Trade Center Health Program are reserved to the Secretary, HHS, to delegate at her discretion; other duties of the Administrator of the World Trade Center Health Program not explicitly reserved to the Secretary, HHS, are assigned to the Director, NIOSH. The administration of the Advisory Committee established under Section 300mm-1(a) is left to the Director of NIOSH in his role as Administrator of the World Trade Center Health Program. CDC and NIOSH provide funding, Start Printed Page 63791staffing, and administrative support services for the Advisory Committee. The charter was reissued on May 12, 2015, and will expire on May 12, 2017.
Matters for Discussion: The Advisory Committee will continue its deliberations from the meeting on June 4, 2015, addressing the need for research on developmental or health effects in children. The agenda will include presentations on children's health research that has been conducted related to exposures from the 9/11 terrorist attacks. Also, a panel of children's researchers will discuss children's research issues with the Advisory Committee.
The agenda is subject to change as priorities dictate.
Public Comment Sign-up and Submissions to the Docket: To sign up to provide public comments or to submit comments to the docket, send information to the NIOSH Docket Office by one of the following means:
Mail: NIOSH Docket Office, Robert A. Taft Laboratories, C-34, 1090 Tusculum Avenue, Cincinnati, Ohio 45226.
Telephone: (513) 533-8611.
In the event an individual cannot attend, written comments may be submitted. The comments should be limited to two pages and submitted through http://www.regulations.gov by November 27, 2015. Efforts will be made to provide the two-page written comments received by the deadline below to the committee members before the meeting. Comments in excess of two pages will be made publicly available at http://www.regulations.gov. To view background information and previous submissions go to NIOSH docket http://www.cdc.gov/niosh/docket/archive/docket248.html , http://www.cdc.gov/niosh/docket/archive/docket248-A.html, and http://www.cdc.gov/niosh/docket/archive/docket248-B.html.
Policy on Redaction of Committee Meeting Transcripts (Public Comment): Transcripts will be prepared and posted to http://www.regulations.gov within 60 days after the meeting. If a person making a comment gives his or her name, no attempt will be made to redact that name. NIOSH will take reasonable steps to ensure that individuals making public comments are aware of the fact that their comments (including their name, if provided) will appear in a transcript of the meeting posted on a public Web site. Such reasonable steps include a statement read at the start of the meeting stating that transcripts will be posted and names of speakers will not be redacted. If individuals in making a statement reveal personal information (e.g., medical information) about themselves, that information will not usually be redacted. The CDC Freedom of Information Act coordinator will, however, review such revelations in accordance with the Freedom of Information Act and, if deemed appropriate, will redact such information. Disclosures of information concerning third party medical information will be redacted.
Contact Person for More Information: Paul J. Middendorf, Ph.D., Designated Federal Officer, NIOSH, CDC, 2400 Century Parkway NE., Mail Stop E-20, Atlanta, GA 30345, telephone 1 (888) 982-4748; email: email@example.com.
The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register Notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention, and the Agency for Toxic Substances and Disease Registry.
Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.
[FR Doc. 2015-26759 Filed 10-20-15; 8:45 am]
BILLING CODE 4163-18-P